Detalles de la búsqueda
1.
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors.
Invest New Drugs;
2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38833067
2.
A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency.
NPJ Precis Oncol;
8(1): 117, 2024 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38789724
3.
Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer patients with antibiotics-induced dysbiosis: a propensity-matched real-world analysis.
J Cancer Res Clin Oncol;
150(4): 216, 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38668936
4.
Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study.
Cancer Treat Res Commun;
39: 100809, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38593512
5.
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.
Lung Cancer;
191: 107557, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38626709
6.
PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Cancer Med;
13(8): e6980, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38651187
7.
Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Onco Targets Ther;
17: 267-280, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38567193
8.
Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
Lung Cancer;
191: 107788, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38593478
9.
Identification of barriers to implementation of precision oncology in patients with rare cancers.
Cancer Sci;
115(6): 2023-2035, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538548
10.
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
Invest New Drugs;
42(3): 261-271, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38530565
11.
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
Cancer Treat Rev;
125: 102720, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38502995
12.
Correction to: Phase I study of the antiTIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Cancer Chemother Pharmacol;
2024 Mar 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38556530
13.
Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study.
Int J Clin Oncol;
29(4): 386-397, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38381163
14.
Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations.
JTO Clin Res Rep;
5(2): 100636, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38361742
15.
Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial.
EClinicalMedicine;
69: 102447, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38333370
16.
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Cancer Chemother Pharmacol;
2024 Jan 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38206370
17.
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
Clin Cancer Res;
30(7): 1264-1272, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38295160
18.
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Cancer Res Commun;
4(1): 226-235, 2024 01 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38181055
19.
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study.
Cancer Chemother Pharmacol;
93(4): 341-352, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38086998
20.
Pimitespib for the treatment of advanced gastrointestinal stromal tumors and other tumors.
Future Oncol;
20(9): 507-519, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38050698